X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Attralus intends to use the proceeds from the financing to advance the Phase 1/2 development of Attralus’ lead PAR therapeutic product, AT-02, a humanized IgG1 monoclonal antibody, in transthyretin-associated amyloidosis and AL amyloidosis.
Lead Product(s): AT-02
Therapeutic Area: Genetic Disease Product Name: AT-02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alpha Wave Ventures
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 06, 2024
Details:
AT-04 is a fusion of our pan amyloid removal (PAR) peptide technology with the Fc component of a human IgG1 antibody. The PAR-peptide can bind to pathological protein fibrils found in neurogenerative diseases. The Fc stimulates the immune system to remove amyloid.
Lead Product(s): AT-04
Therapeutic Area: Neurology Product Name: AT-04
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain.
Lead Product(s): AT-04
Therapeutic Area: Neurology Product Name: AT-04
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Ossianix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 17, 2022
Details:
AT-02 is a full-length, humanized, recombinant immunoglobulin 1 (IgG1) monoclonal antibody (mAb) fusion protein that is being developed to treat systemic amyloidosis (SA).
Lead Product(s): AT-02
Therapeutic Area: Genetic Disease Product Name: AT-02
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
AT-04 is a fusion of our pan-amyloid removal (PAR) peptide technology with Fc component of an IgG1 antibody. The PAR-peptide mediates binding to all types of amyloid and the Fc stimulates immune system to remove amyloid.
Lead Product(s): AT-04
Therapeutic Area: Genetic Disease Product Name: AT-04
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University of Tennessee Graduate School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
In in vitro studies, AT-02 was shown to have subnanomolar binding potency to ATTR and AL amyloid and to opsonize amyloid extracts promoting macrophage-mediated phagocytosis of the amyloid.
Lead Product(s): AT-02
Therapeutic Area: Genetic Disease Product Name: AT-02
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
AT-02 is a fusion of PAR-peptide technology with an IgG1 antibody. The proprietary peptide binds to all types of amyloid and delivers the antibody to the site of disease to stimulate the immune system to remove amyloid.
Lead Product(s): AT-02
Therapeutic Area: Genetic Disease Product Name: AT-02
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
The financing will allow Attralus to further validate their pan-amyloid imaging agent, AT-01, and advance two therapeutic candidates, AT-02 and AT-03, into clinical development for ATTR (transthyretin), AL (light chain) and potentially ALECT2 systemic amyloidosis.
Lead Product(s): AT-02
Therapeutic Area: Genetic Disease Product Name: AT-02
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: venBio Partners
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
